Belite Bio, Inc (BLTE) Stock: Price, Forecast & Analyst Target
Belite Bio, Inc (BLTE) — MoonshotScore 64/100 (Fair band), calculated Nov 18, 2026. Price $127.38 (-15.65%), as of the Nov 20, 2026 trading session; market cap $5.17B. Expected results Mar 1, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Belite Bio, Inc · BLTE · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Belite Bio is a clinical-stage drug developer pursuing oral therapies for retinal disease, led by a candidate designed to limit the buildup of damaging vitamin A metabolites in ocular tissue. It does not yet sell a product, so rising research expense and widening losses describe development intensity rather than customer demand. Clinical validation must ultimately convert that spending into a commercial medicine for the forecast revenue path to become credible.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Belite Bio (BLTE)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Rising.
- quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 4 of the last 8 reports
- ROE -17.0% · ROA -14.0% · current ratio 33.56 · earnings yield -1.7% · free-cash-flow yield -0.0%
Holding back: soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 80 | Strong | |
| 67 | Strong | |
| 67 | Strong | |
| 64 | Fair | |
| 64 | Fair | |
| 64 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $127.38 | |
| Change on the day | -15.65% | |
| 52-week range | $105.88–$200.00 | |
| Market capitalisation | $5.17B | — |
| Shares traded on the day | 1.04M | |
| Beta (volatility vs the S&P 500) | -1.19 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Belite Bio (BLTE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 12, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 12, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Belite Bio (BLTE), and what does it report?
Short answer · as of
Belite Bio’s main program targets Stargardt disease and atrophic age-related macular degeneration through an investigational oral therapy that modulates vitamin A delivery to the eye.
Research dated 2026-09-13.
A separate preclinical oral program extends the platform toward liver and metabolic disorders.
Reported revenue remains absent. The income statement therefore measures research progress indirectly through development expense, administrative cost and net loss, while the compact workforce reinforces the profile of a focused drug developer rather than a commercial pharmaceutical operation.
What do the latest results show for Belite Bio (BLTE)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0.
Research dated 2026-09-13.
The latest results extend a clear pattern: research expense increased, the operating loss widened and the net loss deepened, while administrative expense eased slightly from the preceding period. Recent earnings have nevertheless been less negative than consensus expected, showing better expense outcomes relative to forecasts without changing the precommercial status of the business.
With the retinal candidate in late-stage trials, research spending is the most direct reported link between pipeline advancement and the worsening operating result. The figures support an expense-driven change, not a revenue-driven deterioration, because commercial sales remain absent.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · EPS vs estimate
- Above estimate Nov 12, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 12, 2026 | Not available | Not available | −$0.6000 | −$0.7863 |
| Aug 12, 2026 | Not available | Not available | −$0.7000 | −$0.7300 |
| May 20, 2026 | Not available | Not available | −$0.3400 | −$0.6000 |
| Mar 2, 2026 | Not available | $16.67M | −$0.3800 | −$0.5600 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$28M | -$0.71 (diluted) |
| Q1 FY2026 | $0 | -$27M | -$0.68 (diluted) |
| Q4 FY2025 | $0 | -$25M | -$0.76 (diluted) |
| Sep 2025 | $0 | -$22M | -$0.65 (diluted) |
What are the financial strengths and risks for Belite Bio (BLTE)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Reported debt is absent, liquidity ratios are exceptionally high and the distress screen appears strong. Yet the latest cash and investment balances are nil after earlier observations showed substantial liquidity, while the calculated cash decline spans the full reported window. That uneven balance-sheet picture does not support a dependable runway conclusion on its own.
An isolated operating cash-flow observation appears close to neutral, but recurring net losses and accelerating research expense show that Belite Bio is not economically self-funding. Institutional participation increased modestly, while recent insider activity consisted entirely of sales rather than purchases; neither observation explains the clinical outlook, but each matters if external capital becomes important.
Data-derived red flags
- Negative return on equity (-17.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Belite Bio (BLTE)?
Short answer · as of
The next earnings report is expected on Mar 1, 2027.
Research dated 2026-09-13.
The scheduled earnings update should be read for research spending, administrative discipline and whether the reported cash balance becomes consistent with the earlier liquidity history. A smaller loss relative to expectations would matter less than evidence that late-stage work is advancing without another sharp increase in the expense base.
Longer-range forecasts assume a transition from absent revenue and negative earnings to meaningful sales and profitability, but the wide forecast range signals substantial disagreement about commercialization. Progress in the retinal program is therefore the observation that must connect current spending with those estimates.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Belite Bio compare with its peers?
Short answer
Belite Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Belite Bio differs from a diversified commercial biotechnology company because its value is concentrated in clinical validation rather than a portfolio of marketed products. Its defining feature is an oral approach to retinal disease that aims to control vitamin A metabolite accumulation, paired with an earlier program applying related biology to liver and metabolic conditions.
The compact workforce and absent revenue place the company among focused precommercial developers, but the analyst forecast spread shows unusually divergent commercialization assumptions. That makes comparison through current sales multiples less informative than comparing clinical progress, spending intensity and the durability of funding.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.89 Nov 20, 2026 | $7.38B | 98 5-pillar Nov 18, 2026 | |
| $13.17 Nov 20, 2026 | $2.92B | 97 5-pillar Nov 18, 2026 | |
| $63.62 Nov 20, 2026 | $6.96B | 91 5-pillar Nov 18, 2026 | |
| $26.36 Nov 20, 2026 | $3.33B | 89 5-pillar Nov 18, 2026 | |
| $39.91 Nov 20, 2026 | $4.37B | 84 5-pillar Nov 18, 2026 | |
| $17.58 Nov 20, 2026 | $5.04B | 83 5-pillar Nov 18, 2026 | |
| $46.53 Nov 20, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| $286.85 Nov 20, 2026 | $5.74B | 71 5-pillar Nov 18, 2026 | |
| $17.59 Nov 19, 2026 | $3.04B | 68 5-pillar Nov 18, 2026 | |
| $13.61 Nov 20, 2026 | $4.78B | 67 5-pillar Nov 18, 2026 | |
| $95.81 Nov 20, 2026 | $6.50B | 67 5-pillar Nov 18, 2026 | |
| $119.52 Nov 20, 2026 | $5.04B | 66 5-pillar Nov 18, 2026 | |
| Belite Bio (BLTE) — this page | $127.38 | $5.17B | 64 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $206.00 – $303.00
- Consensus target
- $245.17
- Median target
- $237.50
Consensus record · Captured .
Measured against a quoted price of $127.38 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 29, 2026
- Transactions
- 67
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 63
- Other transactions
- 4
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BLTE in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.40% | $18.02M | Held, unchanged |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Belite Bio (BLTE)?
What Investors Ask About Belite Bio (BLTE) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is Belite Bio trying to change in Stargardt disease?
Its oral retinal candidate is designed to modulate vitamin A delivery and prevent harmful metabolites from accumulating in ocular tissue. Clinical validation carries unusual weight because the company has no commercial revenue while research expense continues to rise.
Why can Belite Bio beat earnings expectations while remaining precommercial?
An earnings beat can result from a loss that is less negative than analysts expected, without any product sales. Recent results cleared consensus expectations while the income statement continued to show absent revenue and substantial development expense.
Does Belite Bio’s reported liquidity establish a dependable trial runway?
The liquidity picture is internally uneven: leverage is absent and liquidity ratios are strong, but the latest cash records are nil after earlier substantial balances. The calculated decline therefore deserves attention alongside future cash disclosures and the rising loss rate.
How does Belite Bio’s liver program fit beside its retinal program?
The earlier-stage oral program targets retinol-binding biology across liver and metabolic disorders, adding scientific breadth beside the late-stage retinal candidate. Financially, the company still reports as a precommercial developer, so that breadth has not produced a separate revenue stream.
What is the BLTE stock price today?
The last price recorded for Belite Bio, Inc (BLTE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BLTE price target?
The analyst consensus price target for Belite Bio, Inc (BLTE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 35 figures on this page — 1 from SEC filings and earnings calls, 28 from Financial Modeling Prep (FMP), 4 with no recorded source, 1 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com